Search details
1.
Augmented Clearance of Nivolumab Is Associated with Renal Functions in Chronic Renal Disease Model Rats.
Drug Metab Dispos
; 50(6): 822-826, 2022 06.
Article
in English
| MEDLINE | ID: mdl-34348939
2.
High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples.
Biomed Chromatogr
; 32(2)2018 Feb.
Article
in English
| MEDLINE | ID: mdl-28762239
3.
Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer.
Lung Cancer
; 178: 247-253, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36913912
4.
Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC.
JTO Clin Res Rep
; 4(4): 100474, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-37007867
5.
Development of an analytical method to determine E7130 concentration in mouse plasma by micro-sampling using ultra-performance liquid chromatography-high resolution mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci
; 1207: 123366, 2022 Sep 01.
Article
in English
| MEDLINE | ID: mdl-35853391
6.
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
J Thorac Oncol
; 17(10): 1227-1232, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35788404
7.
Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients.
Lung Cancer
; 173: 35-42, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36116168
8.
A procedure for method development and protein binding ratio as the indicator of sensitivity with anticancer agents on MALDI mass spectrometry imaging.
Drug Metab Pharmacokinet
; 38: 100385, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-33878680
9.
Use of an alternative signature peptide during development of a LC-MS/MS assay of plasma nivolumab levels applicable for multiple species.
J Chromatogr B Analyt Technol Biomed Life Sci
; 1162: 122489, 2021 Jan 01.
Article
in English
| MEDLINE | ID: mdl-33385769
10.
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis.
Clin Cancer Res
; 27(14): 3970-3979, 2021 07 15.
Article
in English
| MEDLINE | ID: mdl-33980613
11.
The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy.
JTO Clin Res Rep
; 1(1): 100008, 2020 Mar.
Article
in English
| MEDLINE | ID: mdl-34589912
12.
Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging.
Sci Rep
; 10(1): 15535, 2020 09 23.
Article
in English
| MEDLINE | ID: mdl-32968211
13.
Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging.
Sci Rep
; 7(1): 12622, 2017 10 03.
Article
in English
| MEDLINE | ID: mdl-28974758
Results
1 -
13
de 13
1
Next >
>>